Open trial of risperidone in 24 young children with pervasive developmental disorders

Research output: Contribution to journalArticle

Abstract

Objective: To describe tolerability and efficacy of risperidone in very young children with pervasive developmental disorders. Method: Twenty-four children aged 3.6 to 6.6 years (mean 4.6 years ±8 months) enrolled during 1999 and 2000 participated in a 16-week open-label trial with risperidone monotherapy. Outcome measures included the Children's Psychiatric Rating Scale (CPRS), Childhood Autism Rating Scale (CARS), Clinical Global Impression-Improvement (CGI-I), and Children's Global Assessment Scale (C-GAS). Results: Two subjects did not complete the trial because of side effects. The optimal dose was 0.5 mg/day. After the treatment a 21% improvement in CPRS and a 14% improvement in CARS total scores was found. Items related to behavioral control (hyperactivity, fidgetiness, rhythmic motions) and affect regulation (lability of affect, angry affect) improved more than 25%. Based on improvement of at least 25% on the CPRS and a score of 1 or 2 on the CGI-I, eight subjects were considered responders. Functional impairment (C-GAS) improved more than 25%. Thirteen subjects (54%) were free of any side effects; in the other participants risperidone was well tolerated. Only three subjects had a weight gain greater than 10%. Conclusions: Low-dose risperidone may positively affect symptoms in young autistic children, improving disruptive/hyperactive behavior and affective dysregulation. Further controlled studies in this age group are warranted.

Original languageEnglish
Pages (from-to)1206-1214
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume40
Issue number10
Publication statusPublished - 2001

Fingerprint

Risperidone
Child Psychiatry
Autistic Disorder
Weight Gain
Age Groups
Outcome Assessment (Health Care)

Keywords

  • Autistic disorder
  • Children
  • Risperidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

@article{d7f5f0534f3a4c53a50aa1cfbee63307,
title = "Open trial of risperidone in 24 young children with pervasive developmental disorders",
abstract = "Objective: To describe tolerability and efficacy of risperidone in very young children with pervasive developmental disorders. Method: Twenty-four children aged 3.6 to 6.6 years (mean 4.6 years ±8 months) enrolled during 1999 and 2000 participated in a 16-week open-label trial with risperidone monotherapy. Outcome measures included the Children's Psychiatric Rating Scale (CPRS), Childhood Autism Rating Scale (CARS), Clinical Global Impression-Improvement (CGI-I), and Children's Global Assessment Scale (C-GAS). Results: Two subjects did not complete the trial because of side effects. The optimal dose was 0.5 mg/day. After the treatment a 21{\%} improvement in CPRS and a 14{\%} improvement in CARS total scores was found. Items related to behavioral control (hyperactivity, fidgetiness, rhythmic motions) and affect regulation (lability of affect, angry affect) improved more than 25{\%}. Based on improvement of at least 25{\%} on the CPRS and a score of 1 or 2 on the CGI-I, eight subjects were considered responders. Functional impairment (C-GAS) improved more than 25{\%}. Thirteen subjects (54{\%}) were free of any side effects; in the other participants risperidone was well tolerated. Only three subjects had a weight gain greater than 10{\%}. Conclusions: Low-dose risperidone may positively affect symptoms in young autistic children, improving disruptive/hyperactive behavior and affective dysregulation. Further controlled studies in this age group are warranted.",
keywords = "Autistic disorder, Children, Risperidone",
author = "G. Masi and A. Cosenza and M. Mucci and P. Brovedani",
year = "2001",
language = "English",
volume = "40",
pages = "1206--1214",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Open trial of risperidone in 24 young children with pervasive developmental disorders

AU - Masi, G.

AU - Cosenza, A.

AU - Mucci, M.

AU - Brovedani, P.

PY - 2001

Y1 - 2001

N2 - Objective: To describe tolerability and efficacy of risperidone in very young children with pervasive developmental disorders. Method: Twenty-four children aged 3.6 to 6.6 years (mean 4.6 years ±8 months) enrolled during 1999 and 2000 participated in a 16-week open-label trial with risperidone monotherapy. Outcome measures included the Children's Psychiatric Rating Scale (CPRS), Childhood Autism Rating Scale (CARS), Clinical Global Impression-Improvement (CGI-I), and Children's Global Assessment Scale (C-GAS). Results: Two subjects did not complete the trial because of side effects. The optimal dose was 0.5 mg/day. After the treatment a 21% improvement in CPRS and a 14% improvement in CARS total scores was found. Items related to behavioral control (hyperactivity, fidgetiness, rhythmic motions) and affect regulation (lability of affect, angry affect) improved more than 25%. Based on improvement of at least 25% on the CPRS and a score of 1 or 2 on the CGI-I, eight subjects were considered responders. Functional impairment (C-GAS) improved more than 25%. Thirteen subjects (54%) were free of any side effects; in the other participants risperidone was well tolerated. Only three subjects had a weight gain greater than 10%. Conclusions: Low-dose risperidone may positively affect symptoms in young autistic children, improving disruptive/hyperactive behavior and affective dysregulation. Further controlled studies in this age group are warranted.

AB - Objective: To describe tolerability and efficacy of risperidone in very young children with pervasive developmental disorders. Method: Twenty-four children aged 3.6 to 6.6 years (mean 4.6 years ±8 months) enrolled during 1999 and 2000 participated in a 16-week open-label trial with risperidone monotherapy. Outcome measures included the Children's Psychiatric Rating Scale (CPRS), Childhood Autism Rating Scale (CARS), Clinical Global Impression-Improvement (CGI-I), and Children's Global Assessment Scale (C-GAS). Results: Two subjects did not complete the trial because of side effects. The optimal dose was 0.5 mg/day. After the treatment a 21% improvement in CPRS and a 14% improvement in CARS total scores was found. Items related to behavioral control (hyperactivity, fidgetiness, rhythmic motions) and affect regulation (lability of affect, angry affect) improved more than 25%. Based on improvement of at least 25% on the CPRS and a score of 1 or 2 on the CGI-I, eight subjects were considered responders. Functional impairment (C-GAS) improved more than 25%. Thirteen subjects (54%) were free of any side effects; in the other participants risperidone was well tolerated. Only three subjects had a weight gain greater than 10%. Conclusions: Low-dose risperidone may positively affect symptoms in young autistic children, improving disruptive/hyperactive behavior and affective dysregulation. Further controlled studies in this age group are warranted.

KW - Autistic disorder

KW - Children

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=0034804938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034804938&partnerID=8YFLogxK

M3 - Article

C2 - 11589534

AN - SCOPUS:0034804938

VL - 40

SP - 1206

EP - 1214

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 10

ER -